CASP2 and cancer: Lastly, we demonstrated that the combined treatment of ACP52C with a CASP2 inhibitor could induce cell death in resistant cells and ACP52CGK‐α3, a CASP2 inhibiting peptide‐conjugated ACP52CGK, can reduce the cancer burden even in ACP52C‐resistant cancers in a CDX mouse model.